Statement by Joe Boncore, CEO of MassBio, on CMS’ National Coverage Decision to Restrict Coverage for Drugs Used to Treat Patients Suffering from Alzheimer’s Disease

Apr 08, 2022

“CMS’ decision to severely limit patient access to a new class of Alzheimer’s therapies is an unprecedented repudiation of the FDA’s independent, scientific review and approval process and is heartbreaking for Alzheimer’s patients and their families.

FDA approval of a new drug has always been the gold standard of safety and efficiency. Now, CMS – the government health insurance company – is unilaterally deciding that they know better than the FDA despite their lack of scientific expertise.  

Following an increase in Alzheimer’s related deaths throughout the pandemic, patients are counting on timely and efficient access to care. Limiting the potential of crucial treatments is not prioritizing patients and devalues the outstanding milestones scientists and researchers have accomplished to finally provide a treatment to the population suffering from Alzheimer’s disease.

An inability to treat Alzheimer’s was once because the solutions did not exist. Now, even though new solutions are here, bureaucratic restrictions from the federal government are preventing patients from receiving a therapy that could change their life.”

See all MassBio News